Sells prescription medicines for cancer, rare diseases and other conditions to government payers, managed-care organizations and hospitals.
20-F for FY2025, filed Feb 24, 2026Oncology sales in the US increased by 18% to $11,187 million (2024: $9,510 million; 2023: $7,719 million).View ↗
Rare Disease sales in the US increased by 3% to $5,423 million (2024: $5,263 million; 2023: $4,701 million).View ↗
At the time Product Sales are invoiced, rebates and deductions that the Group expects to pay are estimated based upon assumptions developed…View ↗
AstraZeneca sells medicines, with payment tied to when products ship or arrive. It also earns shares or royalties from partner sales and receives upfront or milestone payments for licensed product rights.
20-F for FY2025, filed Feb 24, 2026Product Sales represent net invoice value less estimated rebates, returns and chargebacks, which are considered to be variable…View ↗
Alliance Revenue comprises income arising from the ongoing operation of collaborative arrangements related to sales made by collaboration…View ↗
Collaboration Revenue includes income arising from entering into collaborative arrangements where the Group has out-licensed (sold) certain…View ↗
Where Collaboration Revenue arises from the licensing of the Group’s own intellectual property, the licences we grant are typically rights…View ↗
$58.7B
20-F for FY2025, filed Feb 24, 2026
$58.7B ↗
Customers include government payers and managed-care organizations, healthcare institutions such as hospitals and long-term care facilities, and group purchasing organizations; some partner arrangements involve sales made by collaboration partners.
20-F for FY2025, filed Feb 24, 2026
Yes. It kept 17 cents of every revenue dollar as net income in FY2025 and turned 20 cents into free cash flow.
Growing. Revenue grew 57% in 4 years, from $37.4B in FY2021 to $58.7B in FY2025, about 12% a year.
Loading...